臨床神経学

第50回日本神経学会総会

<シンポジウム4―1>アルツハイマー病の診断と治療開発
アルツハイマー病の発症前診断とMCI

荒井 啓行

東北大学加齢医学研究所加齢・脳神経研究部門加齢老年医学研究分野〔〒980-8575 仙台市青葉区星陵町4-1〕

The clinical diagnosis of Alzheimer's disease (AD) is occasionally imprecise using consensus criteria for probable AD. Therefore, there is a great need for simple biomarkers that substantially aid early diagnosis and tract disease progression of AD and mild cognitive impairment. Of currently available biomarkers for AD, imaging markers are of particular importance based on their low invasiveness and reproducibility. In vivo detection of brain amyloid burden using positron emission tomography either by PIB or BF-227 would be quite attractive. In Japan, Alzheimer's disease neuroimaging initiatives (ADNI) has been launched in 2008 in accordance with US- and World-Wide ADNI. The paradigm of AD diagnosis and treatment would be shifted from "cognitive-based" to "biomarker-based" framework. The use of ideal biomarkers can remarkably speed up AD drug discovery by providing earliest signals of drug efficacy.
Full Text of this Article in Japanese PDF (284K)

(臨床神経, 49:838−840, 2009)
key words:アルツハイマー病, アミロイドイメージング, PIB, BF-227, ADNI

(受付日:2009年5月21日)